Brief Report: Prevalence of Posttreatment Controller Phenotype Is Rare in HIV-Infected Persons After Stopping Antiretroviral Therapy

Posttreatment control of HIV infection is a rare phenomenon primarily described among those initiating treatment with antiretroviral therapy (ART) during early/acute HIV infection. We examined a large, well-characterized cohort of HIV-infected Department of Defense beneficiaries for the presence of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of acquired immune deficiency syndromes (1999) 2017-07, Vol.75 (3), p.364-369
Hauptverfasser: Perkins, Matthew J, Bradley, William P, Lalani, Tahaniyat, Agan, Brian K, Whitman, Timothy J, Ferguson, Tomas M, Okulicz, Jason F, Ganesan, Anuradha
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 369
container_issue 3
container_start_page 364
container_title Journal of acquired immune deficiency syndromes (1999)
container_volume 75
creator Perkins, Matthew J
Bradley, William P
Lalani, Tahaniyat
Agan, Brian K
Whitman, Timothy J
Ferguson, Tomas M
Okulicz, Jason F
Ganesan, Anuradha
description Posttreatment control of HIV infection is a rare phenomenon primarily described among those initiating treatment with antiretroviral therapy (ART) during early/acute HIV infection. We examined a large, well-characterized cohort of HIV-infected Department of Defense beneficiaries for the presence of posttreatment controllers (PTCs) whom we defined as individuals with sustained viral suppression for ≥6 months after discontinuation of ART. We defined those who became viremic within 6 months of discontinuing ART as rapid viremics (RVs) and compared demographic and clinical characteristics, CD4 counts, and viral loads prior, during, and after ART discontinuation between the 2 groups. From a cohort of 6070 patients, we identified 95 who had been treated with ART for 2 years or more who subsequently discontinued ART and had viral load assessments available after discontinuation. Four (4.2%) of these 95 met our definition of PTC. The duration of viral suppression off of ART ranged from 267 to 1058 days with 1 of the 4 restarting ART without having redeveloped a significant viremia. All 4 patients initiated ART during chronic HIV infection. Demographic and clinical characteristics of PTCs were similar to RVs. While posttreatment control has predominantly been described among individuals who initiated ART in early/acute HIV infection, we identified 4 PTCs who started ART during chronic infection suggesting that posttreatment control also occurs among such patients. The rarity of PTCs identified in our cohort is consistent with reports from previous studies.
doi_str_mv 10.1097/QAI.0000000000001393
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1886753663</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1886753663</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2963-a04ac08212b4a5ca994024ab6bdd2b1c2107d918d02a4f865f31b71a4e0804e53</originalsourceid><addsrcrecordid>eNpdkU1v1DAQhi1ERb_4BwhZ4sIlxd-xuS0raCNV6rYUrpGTTGiqrB3G3kp754dj1IJQ5zJzeN5XIz2EvOHsjDNXf7heNWfsv-HSyRfkiDulqtpa9bLcWuhKcakPyXFK94UxSrlX5FBY6ZTV5oj8-oQTjPQGloj5I90gPPgZQg80jnQTU84IPm8hZLqOIWOcZ0C6uYMQ834B2iR64xHoFOhF871qwgh9hoFuAFMMia7GXPivOS7LFH7QVcgTQql5mNDP9PYO0C_7U3Iw-jnB66d9Qr59-Xy7vqgur86b9eqy6oUzsvJM-Z5ZwUWnvO69c4oJ5TvTDYPoeC84qwfH7cCEV6M1epS8q7lXwCxToOUJef_Yu2D8uYOU2-2UephnHyDuUsutNbWWxsiCvnuG3scdhvJdy51QhhttXaHUI9VjTAlhbBecth73LWftH0ttsdQ-t1Rib5_Kd90Whn-hv1rkb98YjVk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1924616589</pqid></control><display><type>article</type><title>Brief Report: Prevalence of Posttreatment Controller Phenotype Is Rare in HIV-Infected Persons After Stopping Antiretroviral Therapy</title><source>Freely Accessible Journals</source><source>MEDLINE</source><source>Journals@Ovid LWW Legacy Archive</source><source>Journals@Ovid Complete</source><creator>Perkins, Matthew J ; Bradley, William P ; Lalani, Tahaniyat ; Agan, Brian K ; Whitman, Timothy J ; Ferguson, Tomas M ; Okulicz, Jason F ; Ganesan, Anuradha</creator><creatorcontrib>Perkins, Matthew J ; Bradley, William P ; Lalani, Tahaniyat ; Agan, Brian K ; Whitman, Timothy J ; Ferguson, Tomas M ; Okulicz, Jason F ; Ganesan, Anuradha</creatorcontrib><description>Posttreatment control of HIV infection is a rare phenomenon primarily described among those initiating treatment with antiretroviral therapy (ART) during early/acute HIV infection. We examined a large, well-characterized cohort of HIV-infected Department of Defense beneficiaries for the presence of posttreatment controllers (PTCs) whom we defined as individuals with sustained viral suppression for ≥6 months after discontinuation of ART. We defined those who became viremic within 6 months of discontinuing ART as rapid viremics (RVs) and compared demographic and clinical characteristics, CD4 counts, and viral loads prior, during, and after ART discontinuation between the 2 groups. From a cohort of 6070 patients, we identified 95 who had been treated with ART for 2 years or more who subsequently discontinued ART and had viral load assessments available after discontinuation. Four (4.2%) of these 95 met our definition of PTC. The duration of viral suppression off of ART ranged from 267 to 1058 days with 1 of the 4 restarting ART without having redeveloped a significant viremia. All 4 patients initiated ART during chronic HIV infection. Demographic and clinical characteristics of PTCs were similar to RVs. While posttreatment control has predominantly been described among individuals who initiated ART in early/acute HIV infection, we identified 4 PTCs who started ART during chronic infection suggesting that posttreatment control also occurs among such patients. The rarity of PTCs identified in our cohort is consistent with reports from previous studies.</description><identifier>ISSN: 1525-4135</identifier><identifier>EISSN: 1944-7884</identifier><identifier>DOI: 10.1097/QAI.0000000000001393</identifier><identifier>PMID: 28394856</identifier><language>eng</language><publisher>United States: Lippincott Williams &amp; Wilkins Ovid Technologies</publisher><subject>Adult ; AIDS/HIV ; Anti-HIV Agents - therapeutic use ; Antiretroviral agents ; Antiretroviral drugs ; Antiretroviral therapy ; CD4 antigen ; CD4 Lymphocyte Count ; Chronic infection ; Demographics ; Disease control ; Disease Progression ; Drug Administration Schedule ; Female ; Genotype &amp; phenotype ; HIV ; HIV Infections - drug therapy ; HIV Infections - immunology ; HIV Long-Term Survivors - statistics &amp; numerical data ; Human immunodeficiency virus ; Humans ; Male ; Military Personnel ; Patients ; Prevalence ; Restarting ; Retrospective Studies ; RNA, Viral ; Therapy ; Viral Load ; Viremia ; Viremia - immunology</subject><ispartof>Journal of acquired immune deficiency syndromes (1999), 2017-07, Vol.75 (3), p.364-369</ispartof><rights>Copyright Lippincott Williams &amp; Wilkins Jul 1, 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2963-a04ac08212b4a5ca994024ab6bdd2b1c2107d918d02a4f865f31b71a4e0804e53</citedby><cites>FETCH-LOGICAL-c2963-a04ac08212b4a5ca994024ab6bdd2b1c2107d918d02a4f865f31b71a4e0804e53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28394856$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Perkins, Matthew J</creatorcontrib><creatorcontrib>Bradley, William P</creatorcontrib><creatorcontrib>Lalani, Tahaniyat</creatorcontrib><creatorcontrib>Agan, Brian K</creatorcontrib><creatorcontrib>Whitman, Timothy J</creatorcontrib><creatorcontrib>Ferguson, Tomas M</creatorcontrib><creatorcontrib>Okulicz, Jason F</creatorcontrib><creatorcontrib>Ganesan, Anuradha</creatorcontrib><title>Brief Report: Prevalence of Posttreatment Controller Phenotype Is Rare in HIV-Infected Persons After Stopping Antiretroviral Therapy</title><title>Journal of acquired immune deficiency syndromes (1999)</title><addtitle>J Acquir Immune Defic Syndr</addtitle><description>Posttreatment control of HIV infection is a rare phenomenon primarily described among those initiating treatment with antiretroviral therapy (ART) during early/acute HIV infection. We examined a large, well-characterized cohort of HIV-infected Department of Defense beneficiaries for the presence of posttreatment controllers (PTCs) whom we defined as individuals with sustained viral suppression for ≥6 months after discontinuation of ART. We defined those who became viremic within 6 months of discontinuing ART as rapid viremics (RVs) and compared demographic and clinical characteristics, CD4 counts, and viral loads prior, during, and after ART discontinuation between the 2 groups. From a cohort of 6070 patients, we identified 95 who had been treated with ART for 2 years or more who subsequently discontinued ART and had viral load assessments available after discontinuation. Four (4.2%) of these 95 met our definition of PTC. The duration of viral suppression off of ART ranged from 267 to 1058 days with 1 of the 4 restarting ART without having redeveloped a significant viremia. All 4 patients initiated ART during chronic HIV infection. Demographic and clinical characteristics of PTCs were similar to RVs. While posttreatment control has predominantly been described among individuals who initiated ART in early/acute HIV infection, we identified 4 PTCs who started ART during chronic infection suggesting that posttreatment control also occurs among such patients. The rarity of PTCs identified in our cohort is consistent with reports from previous studies.</description><subject>Adult</subject><subject>AIDS/HIV</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antiretroviral agents</subject><subject>Antiretroviral drugs</subject><subject>Antiretroviral therapy</subject><subject>CD4 antigen</subject><subject>CD4 Lymphocyte Count</subject><subject>Chronic infection</subject><subject>Demographics</subject><subject>Disease control</subject><subject>Disease Progression</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Genotype &amp; phenotype</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - immunology</subject><subject>HIV Long-Term Survivors - statistics &amp; numerical data</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Male</subject><subject>Military Personnel</subject><subject>Patients</subject><subject>Prevalence</subject><subject>Restarting</subject><subject>Retrospective Studies</subject><subject>RNA, Viral</subject><subject>Therapy</subject><subject>Viral Load</subject><subject>Viremia</subject><subject>Viremia - immunology</subject><issn>1525-4135</issn><issn>1944-7884</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU1v1DAQhi1ERb_4BwhZ4sIlxd-xuS0raCNV6rYUrpGTTGiqrB3G3kp754dj1IJQ5zJzeN5XIz2EvOHsjDNXf7heNWfsv-HSyRfkiDulqtpa9bLcWuhKcakPyXFK94UxSrlX5FBY6ZTV5oj8-oQTjPQGloj5I90gPPgZQg80jnQTU84IPm8hZLqOIWOcZ0C6uYMQ834B2iR64xHoFOhF871qwgh9hoFuAFMMia7GXPivOS7LFH7QVcgTQql5mNDP9PYO0C_7U3Iw-jnB66d9Qr59-Xy7vqgur86b9eqy6oUzsvJM-Z5ZwUWnvO69c4oJ5TvTDYPoeC84qwfH7cCEV6M1epS8q7lXwCxToOUJef_Yu2D8uYOU2-2UephnHyDuUsutNbWWxsiCvnuG3scdhvJdy51QhhttXaHUI9VjTAlhbBecth73LWftH0ttsdQ-t1Rib5_Kd90Whn-hv1rkb98YjVk</recordid><startdate>20170701</startdate><enddate>20170701</enddate><creator>Perkins, Matthew J</creator><creator>Bradley, William P</creator><creator>Lalani, Tahaniyat</creator><creator>Agan, Brian K</creator><creator>Whitman, Timothy J</creator><creator>Ferguson, Tomas M</creator><creator>Okulicz, Jason F</creator><creator>Ganesan, Anuradha</creator><general>Lippincott Williams &amp; Wilkins Ovid Technologies</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7T5</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20170701</creationdate><title>Brief Report: Prevalence of Posttreatment Controller Phenotype Is Rare in HIV-Infected Persons After Stopping Antiretroviral Therapy</title><author>Perkins, Matthew J ; Bradley, William P ; Lalani, Tahaniyat ; Agan, Brian K ; Whitman, Timothy J ; Ferguson, Tomas M ; Okulicz, Jason F ; Ganesan, Anuradha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2963-a04ac08212b4a5ca994024ab6bdd2b1c2107d918d02a4f865f31b71a4e0804e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>AIDS/HIV</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antiretroviral agents</topic><topic>Antiretroviral drugs</topic><topic>Antiretroviral therapy</topic><topic>CD4 antigen</topic><topic>CD4 Lymphocyte Count</topic><topic>Chronic infection</topic><topic>Demographics</topic><topic>Disease control</topic><topic>Disease Progression</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Genotype &amp; phenotype</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - immunology</topic><topic>HIV Long-Term Survivors - statistics &amp; numerical data</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Male</topic><topic>Military Personnel</topic><topic>Patients</topic><topic>Prevalence</topic><topic>Restarting</topic><topic>Retrospective Studies</topic><topic>RNA, Viral</topic><topic>Therapy</topic><topic>Viral Load</topic><topic>Viremia</topic><topic>Viremia - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Perkins, Matthew J</creatorcontrib><creatorcontrib>Bradley, William P</creatorcontrib><creatorcontrib>Lalani, Tahaniyat</creatorcontrib><creatorcontrib>Agan, Brian K</creatorcontrib><creatorcontrib>Whitman, Timothy J</creatorcontrib><creatorcontrib>Ferguson, Tomas M</creatorcontrib><creatorcontrib>Okulicz, Jason F</creatorcontrib><creatorcontrib>Ganesan, Anuradha</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of acquired immune deficiency syndromes (1999)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Perkins, Matthew J</au><au>Bradley, William P</au><au>Lalani, Tahaniyat</au><au>Agan, Brian K</au><au>Whitman, Timothy J</au><au>Ferguson, Tomas M</au><au>Okulicz, Jason F</au><au>Ganesan, Anuradha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Brief Report: Prevalence of Posttreatment Controller Phenotype Is Rare in HIV-Infected Persons After Stopping Antiretroviral Therapy</atitle><jtitle>Journal of acquired immune deficiency syndromes (1999)</jtitle><addtitle>J Acquir Immune Defic Syndr</addtitle><date>2017-07-01</date><risdate>2017</risdate><volume>75</volume><issue>3</issue><spage>364</spage><epage>369</epage><pages>364-369</pages><issn>1525-4135</issn><eissn>1944-7884</eissn><abstract>Posttreatment control of HIV infection is a rare phenomenon primarily described among those initiating treatment with antiretroviral therapy (ART) during early/acute HIV infection. We examined a large, well-characterized cohort of HIV-infected Department of Defense beneficiaries for the presence of posttreatment controllers (PTCs) whom we defined as individuals with sustained viral suppression for ≥6 months after discontinuation of ART. We defined those who became viremic within 6 months of discontinuing ART as rapid viremics (RVs) and compared demographic and clinical characteristics, CD4 counts, and viral loads prior, during, and after ART discontinuation between the 2 groups. From a cohort of 6070 patients, we identified 95 who had been treated with ART for 2 years or more who subsequently discontinued ART and had viral load assessments available after discontinuation. Four (4.2%) of these 95 met our definition of PTC. The duration of viral suppression off of ART ranged from 267 to 1058 days with 1 of the 4 restarting ART without having redeveloped a significant viremia. All 4 patients initiated ART during chronic HIV infection. Demographic and clinical characteristics of PTCs were similar to RVs. While posttreatment control has predominantly been described among individuals who initiated ART in early/acute HIV infection, we identified 4 PTCs who started ART during chronic infection suggesting that posttreatment control also occurs among such patients. The rarity of PTCs identified in our cohort is consistent with reports from previous studies.</abstract><cop>United States</cop><pub>Lippincott Williams &amp; Wilkins Ovid Technologies</pub><pmid>28394856</pmid><doi>10.1097/QAI.0000000000001393</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1525-4135
ispartof Journal of acquired immune deficiency syndromes (1999), 2017-07, Vol.75 (3), p.364-369
issn 1525-4135
1944-7884
language eng
recordid cdi_proquest_miscellaneous_1886753663
source Freely Accessible Journals; MEDLINE; Journals@Ovid LWW Legacy Archive; Journals@Ovid Complete
subjects Adult
AIDS/HIV
Anti-HIV Agents - therapeutic use
Antiretroviral agents
Antiretroviral drugs
Antiretroviral therapy
CD4 antigen
CD4 Lymphocyte Count
Chronic infection
Demographics
Disease control
Disease Progression
Drug Administration Schedule
Female
Genotype & phenotype
HIV
HIV Infections - drug therapy
HIV Infections - immunology
HIV Long-Term Survivors - statistics & numerical data
Human immunodeficiency virus
Humans
Male
Military Personnel
Patients
Prevalence
Restarting
Retrospective Studies
RNA, Viral
Therapy
Viral Load
Viremia
Viremia - immunology
title Brief Report: Prevalence of Posttreatment Controller Phenotype Is Rare in HIV-Infected Persons After Stopping Antiretroviral Therapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T13%3A17%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Brief%20Report:%20Prevalence%20of%20Posttreatment%20Controller%20Phenotype%20Is%20Rare%20in%20HIV-Infected%20Persons%20After%20Stopping%20Antiretroviral%20Therapy&rft.jtitle=Journal%20of%20acquired%20immune%20deficiency%20syndromes%20(1999)&rft.au=Perkins,%20Matthew%20J&rft.date=2017-07-01&rft.volume=75&rft.issue=3&rft.spage=364&rft.epage=369&rft.pages=364-369&rft.issn=1525-4135&rft.eissn=1944-7884&rft_id=info:doi/10.1097/QAI.0000000000001393&rft_dat=%3Cproquest_cross%3E1886753663%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1924616589&rft_id=info:pmid/28394856&rfr_iscdi=true